Abstract
Any approach applied to drug discovery and development by the medical community and pharmaceutical industry has a direct impact on the future availability of improved, novel, and curative therapies for patients with cancer. By definition, drug discovery is a complex learning process whereby research efforts are directed toward uncovering and assimilating new knowledge to create and develop a drug for the purpose of providing benefit to a defined patient population. Accordingly, a highly desirable technology or approach to drug discovery should facilitate both effective learning and the application of newly discovered observations that can be exploited for therapeutic benefit. However, some believe that drug discovery is largely accomplished by serendipity and therefore appropriately addressed by screening a large number of compounds. Clearly, this approach has not generated an abundance of new drugs for cancer patients and suggests that a tangibly different approach in drug discovery is warranted. We employ an alternative approach to drug discovery, which is based on the elucidation and exploitation of biological, pharmacological, and biochemical mechanisms that have not been previously recognized or fully understood. Mechanism-based drug discovery involves the combined application of physics-based computer simulations and laboratory experimentation. There is increasing evidence that agreement between simulations based on the laws of physics and experimental observations results in a higher probability that such observations are more accurate and better understood as compared with either approach used alone. Physics-based computer simulation applied to drug discovery is now considered by experts in the field to be one of the ultimate methodologies for drug discovery. However, the ability to perform truly comprehensive physics-based molecular simulations remains limited by several factors, including the enormous computer-processing power that is required to perform the formidable mathematical operations and data processing (e.g. memory bandwidth, data storage and retrieval). Another major consideration is the development of software that can generate an appropriate and increasingly complex physical representation of the atomic arrangements of biological systems. During the past 17 years, we have made tremendous progress in addressing some of these obstacles by developing and optimizing physics-based computer programs for the purpose of obtaining increasingly accurate and precise information and by improving the speed of computation. To perform physics-based simulations that involve complex systems of biological and pharmaceutical interest, we have developed methods that enable us to exceed Moore's law. This has been accomplished by parallel processing as well as other methods that have enabled us to study more complex and relevant molecular systems of interest. This paper provides an overview of our approach to drug discovery and describes a novel drug, currently in clinical development, which has directly resulted from the application of this approach.
Similar content being viewed by others
References
Anderson PJ (1979) The structure and amount of tubulin in cells and tissues. J Biol Chem 254:2168
Brock N, Pohl J, Stekar J, Scheef W (1982) Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention—III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). Eur J Cancer Clin Oncol 18:1377
Cavalletti E, Cavaletti G, Tredici G, Oggioni N, Spinelli S, Reddy D, Parker A, Yao S, Zhao M, Wu M, Hausheer F (1999) Oral and intravenous BNP7787 protects against paclitaxel-mediated neurotoxicity in Wistar rats (abstract 2632). Proc Am Assoc Cancer Res
Connelly E, Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J (1996) Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity. Gynecol Oncol 62:166
Deneke SM, Fanburg BL (1989) Regulation of cellular glutathione. Am J Physiol 257:L163
Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff VA (1948) Temporary remissions in acute leukemia in children produced by folic antagonist 4-amethopteroylglutamic acid (aminopterin). N Engl J Med 238:787
Fleming A (1929) On the antibacterial action of culture of a penicillium, with special reference to their use in the isolation of B. influenza. Br J Exp Pathol 10:226
Gilbert HF (1990) Molecular and cellular aspects of thiol–disulfide exchange. Adv Enzymol Relat Areas Mol Biol 63:69
Gilbert HF (1995) Thiol/disulfide exchange equilibria and disulfide bond stability. Methods Enzymol 251:8
Gilman A (1963) The initial clinical trial of nitrogen mustard. Am J Surg 105:574
Hausheer FH, Kanter P, Cao S, Haridas K, Seetharamulu P, Reddy D, Petluru P, Zhao M, Murali D, Saxe JD, Yao S, Martinez N, Zukowski A, Rustum YM (1998) Modulation of platinum-induced toxicities and therapeutic index: mechanistic insights and first- and second-generation protecting agents. Semin Oncol 25:584
Hausheer F, Kochat H, Reddy D, Zhao M, Seetharamulu P, Yao S, Pavankumar P, Murali D, Wu M, Saxe J, Parker A, Hamilton S, Huang Q, Chen X, Berghorn E (2000) BNP7787: a novel chemoprotecting agent for platinum and taxane toxicity (abstract 4890). Proc Am Assoc Cancer Res
Hausheer F, Kochat H, Zhao A, Hamilton S, Wu M, Seetharamulu P, Petluru P, Yao S, Huang Q, Chen X, Ma H, Ding D, Leverett B, Wu Y, Wang J, Saxe J, Parker A, Berghorn E (2001) BNP7787, a novel neuroprotective agent in taxane and platinum regimens, does not interfere with chemotherapeutic effects (abstract 1990). Proc Am Assoc Cancer Res
Heidelberger C, Chaudhuri NK, Danenberg P, Mooren D, Griesbach L, Duschinsky R, Schnitzer RJ, Pleven E, Scheiner J (1957) Fluorinated pyrimidines: a new class of antitumor compounds. Nature 179:663
Kleinman WA, Richie JP (2000) Status of glutathione and other thiols and disulfides in human plasma. Biochem Pharmacol 60:19
Pavankumar PNV, Seetharamulu S, Yao S, Saxe JD, Dasharatha GR, Hausheer FH (1999) Comprehensive ab initio quantum mechanical and molecular orbital (MO) analysis of cisplatin: structure, bonding, charge density, and vibrational frequencies. J Comput Chem 20:365
Pharmaceutical Research and Manufacturers of America (PhRMA) Annual Report 2001–2002, p 13
Rosell R, Gatzemeier U, Betticher DC, Keppler U, Macha HN, Pirker R, Berthet P, Breau JL, Lianes P, Nicholson M, Ardizzoni A, Chemaissani A, Bogaerts J, Gallant G (2002) Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539
Rosenberg B (1985) Fundamental studies with cisplatin. Cancer 55:2303
Rosenberg B, Van Camp L, Grimley EB, Thomson AJ (1967) The inhibition of growth or cell division in Escherichia coli by different ionic species of platinum (IV) complexes. J Biol Chem 242:1347
Schafer FQ, Buettner G (2001) Redox enviroment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic Biol Med 30:1191
Schiff PB, Horwitz SB (1981) Taxol assembles tubulin in the absence of exogenous guanosine 5′-triphosphate or microtubule associated proteins. Biochemistry 20:3247
Schiff PB, Fant J, Horwitz SB (1979) Promotion of microtubule assembly in vitro by taxol. Nature 277:665
Stein AF, Dills RL, Klaasen CD (1986) High-performance liquid chromatographic analysis of glutathione and its thiol and disulfide degradation products. J Chromatogr 381:259
Tufts Center for the Study of Drug Development (2003) Impact Report: Post-approval R&D raises total drug development costs to US$ 800 million. Vol. 5, No. 3, May/June 2003, http://csdd.tufts.edu/NewsEvents/RecentNews.asp?newsid=4
Verschraagen M, Boven E, Ruijter R, van der Born K, Berkhof J, Hausheer FH, van der Vijgh WJF (2003) Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites. Clin Pharmacol Ther (in press)
Wall ME, Wani MC (1995) Camptothecin and taxol: discovery to clinic. Thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 55:753
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was presented at the 18th Bristol-Myers Squibb Nagoya International Cancer Treatment Symposium, "New Strategies for Novel Anticancer Drug Development", 8–9 November 2002, Nagoya, Japan.
Rights and permissions
About this article
Cite this article
Hausheer, F.H., Kochat, H., Parker, A.R. et al. New approaches to drug discovery and development: a mechanism-based approach to pharmaceutical research and its application to BNP7787, a novel chemoprotective agent. Cancer Chemother Pharmacol 52 (Suppl 1), 3–15 (2003). https://doi.org/10.1007/s00280-003-0653-5
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-003-0653-5